BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
As CRISPR and prime editing applications advance, researchers increasingly rely on longer guide RNAs to boost editing efficiency and reduce off-target effects
Glucon-D maintained its leadership position with a 59% MAT market share
Subscribe To Our Newsletter & Stay Updated
